UNIVERSITY OF SHARJAH
COLLEGE OF PHARMACY

Ahmad Abuhelwa
FACULTY MEMBER CREDENTIALS

جـامعـة الشـارقـة
UNIVERSITY OF SHARJAH

First Name	Ahmad
Last Name	Abuhelwa
Job Title	Associate Professor
Nationality	Australian
Gender	Male
Email	Ahmad.abuhelwa@sharjah.ac.ae
Telephone	06-505-7467
Room	Office: E1-121

EDUCATIONAL BACKGROUND
From Recent to Older

From		**To**		
MM	YY	MM	YY	
	2014		2017	Ph.D. Clinical Pharmacology — Pharmacometrics University of South Australia, Australia
	2009		2011	M.Sc. Pharmacy — GPA: 3.8 / 4.0 University of Iowa, USA
	2004		2009	B.Sc. Pharmacy — GPA: 3.94 / 4.0 University of Jordan, Jordan

PROFESSIONAL SUMMARY
From Recent to Older

From		To			Notes
MM	YY	MM	YY		(e.g. To date, on leave, etc)
06	2025			**Associate Professor (Pharmacotherapeutics)** College of Pharmacy, Department of Pharmacy Practice and Pharmacotherapeutics, University of Sharjah, UAE Teaching: Graduate – Pharmacogenomics, Molecular Pharmacology, Foundation of Pharmaceutical Sciences; Undergraduate – Integrated Pharmacology and Therapeutics, Clinical Pharmacology, Pharmacogenomics and Personalized Medicine, Pathophysiology, Human Anatomy and Physiology. Research: Predictors of exposure, therapeutic and adverse effects of medicines used in the treatment of solid tumors and hematological cancers.	To date
	2022		2025	**Assistant Professor (Pharmacotherapeutics)** College of Pharmacy, Department of Pharmacy Practice and Pharmacotherapeutics, University of Sharjah, UAE Teaching: Graduate – Pharmacogenomics, Molecular Pharmacology, Foundation of Pharmaceutical Sciences; Undergraduate – Integrated Pharmacology and Therapeutics, Clinical Pharmacology, Pharmacogenomics and Personalized Medicine, Pathophysiology, Human Anatomy and Physiology. Research: Predictors of exposure, therapeutic and adverse effects of medicines used in the treatment of solid tumors and hematological cancers.	
	2020		2022	**Assistant Professor (Level B Research Fellow)** College of Medicine and Public Health, Department of Pharmacology, Flinders University, Australia Teaching: Skills for Medical Scientists (MDSC3000). Research: Machine learning for personalized prediction of therapeutic outcomes and toxicities to anticancer treatments.	
	2017		2020	**Assistant Professor (Level B Research Fellow)** College of Pharmacy, UniSA Clinical and Health Sciences, University of South Australia, Australia Teaching: Pharmacology (A, B, C), Fundamentals of Pharmacology, Health Professional Essentials, Dosage Form Design. Research: Model-based methods to inform drug development.	

From		To			Notes
MM	YY	MM	YY		(e.g. To date, on leave, etc)
	2017		2017	**Course Developer** College of Pharmacy, UniSA Clinical and Health Sciences, University of South Australia, Australia Teaching: Designed structure and outlined requirements for conducting Objective Structured Clinical Examination (OSCE) for students in Pharmacy Practice III.	
	2017		2017	**Pharmacometrics Consultant Therapeutic Goods Administration (TGA), Australia** Project: Evaluation of PK/PD analyses for a new drug application for treatment of rheumatoid arthritis.	Consultancy
	2015		2016	**Pharmacometrics Consultant Mayne Pharma Pty Ltd, Australia** Projects: Population IVIVC model for Sporanox and SUBA-itraconazole linking gastrointestinal transit time, pH, and pharmacokinetics. Tumour progression pharmacodynamic model for total target lesion burden in basal cell carcinoma patients receiving SUBA-itraconazole.	Consultancy
	2014		2017	**PhD Candidate** College of Pharmacy, UniSA Clinical and Health Sciences, University of South Australia, Australia Thesis: "Population-based models of the effect of food and pH on oral drug absorption."	
	2012		2014	**Research Associate** College of Pharmacy, Department of Pharmaceutical Sciences, Qatar University, Qatar Research: Transdermal drug delivery of the anticancer agent letrozole.	
	2011		2012	**Teaching Assistant** College of Pharmacy, Department of Pharmaceutical Sciences, University of Jordan, Jordan Teaching: Industrial Pharmacy Practicals.	
	2009		2010	**Teaching Assistant** College of Pharmacy, Department of Pharmaceutics and Pharmacotherapeutics, University of Iowa, USA Teaching: Pharmacy Practice Labs (PPLs) I, II, III, IV.	

PUBLICATIONS (SELECTED)
From Recent to Older

YY	Selected publications
2026	Zenati RA, Qannita RA, **Abuhelwa AY**, Alqudah MAY, Aleidi SM, El-Huneidi W, Abu-Gharbieh E, AlShareef ZM, Alzoubi KH, Guella A, Bustanji Y, Semreen MH. Multi-omics insights into systemic molecular alterations and emerging therapeutic targets in diabetic retinopathy. Pharm Pract (Granada). 2026;24(3):1–19. https://pharmacypractice.org/index.php/pp/article/view/3655

September 2026 **Ahmad Abuhelwa**

YY	Selected publications
2026	Alkhoujah SMM, Zenati RA, Ahmed M, Jaber S, **Abuhelwa AY**, Aleidi SM, Farheen S, Albohy A, Khabour OF, Masadeh MM, AlShareef ZM, Bustanji Y, Alzoubi KH, Semreen MH. Edaravone provides neuroprotection against chronic heat stress–induced behavioral dysfunction through adaptive proteomic remodeling. Naunyn Schmiedebergs Arch Pharmacol. 2026. https://doi.org/10.1007/s00210-026-05686-y
2026	Bustanji Y, Harb AA, Taneera J, Aleidi SM, Darwish R, **Abuhelwa AY**, Al-Masri M, Hamad I, Al-Rabi K, El-Huneidi W, Abu-Gharbieh E, Semreen MH. Five decades of cancer research in Jordan: A thematic mapping of clinical, translational, and emerging technological trends (1974–2024). Int J One Health. 2026;12(2):270–291. https://doi.org/10.14202/IJOH.2026.270-291
2026	Ahmed M, Zenati RA, Alkhoujah SM, **Abuhelwa AY**, Aleidi SM, Alqudah MAY, El-Huneidi W, Abu-Gharbieh E, AlShareef ZM, Alzoubi KH, Bustanji Y, Semreen MH. Decoding Chemobrain: Insights from Multi-omics Approaches. Curr Neuropharmacol. 2026. Online ahead of print. https://doi.org/10.2174/011570159X457578260709230856
2026	Jarrah MM, Al-Shamsi HO, Abuhelwa Z, Bustanji Y, Semreen MH, McKinnon RA, Sorich MJ, Hopkins AM, **Abuhelwa AY**. Treatment-specific prediction models in multiple myeloma: a critical review of current evidence and future directions. Eur J Haematol. 2026;117(1):100–116. https://doi.org/10.1111/ejh.70177
2026	Chhetri R, Modi ND, Menz BD, Cornelisse E, Postma D, Kuderer NM, Lyman GH, Swain SM, Li LX, **Abuhelwa AY**, McKinnon RA, Vatandoust S, Kichenadasse G, Rowland A, Sorich MJ, Hopkins AM. Sex-based prognosis in industry-sponsored advanced solid tumor trials: an individual participant data meta-analysis of survival and adverse events. J Natl Cancer Inst. 2026;118(7):1219–1228. https://doi.org/10.1093/jnci/djag046
2026	Ahmed M, Zenati RA, Alkhoujah SM, **Abuhelwa AY**, Alqudah MAY, Aleidi SM, Al-Hroub HM, Alhusban AY, Albohy A, Abu-Gharbieh E, Bustanji Y, Alzoubi KH, Semreen MH. The effects of chemotherapy on brain regions: implications for chemobrain revealed through metabolomic profiling. Naunyn Schmiedebergs Arch Pharmacol. 2026. https://doi.org/10.1007/s00210-026-05529-w
2026	Qannita RA, Zenati RA, **Abuhelwa AY**, Alqudah MAY, Aleidi SM, El-Huneidi W, Abu-Gharbieh E, AlShareef ZM, Alzoubi KH, Bustanji Y, Semreen MH. Emerging biomarkers for early detection of colorectal cancer. Clin Chim Acta. 2026; 589:121013. https://doi.org/10.1016/j.cca.2026.121013
2026	Bustanji Y, Al-Omari L, Taneera J, Aleidi SM, **Abuhelwa AY**, Nabulsi Z, Hamad I, Abu-Rish EY, Semreen MH, El-Huneidi W, Abu-Gharbieh E. Mapping non-coding RNAs (ncRNAs) in cancer research: Bibliometric trends, emerging themes, and implications for diagnostics and therapy. Advancements in Life Sciences. 2026;13(1):4001. https://doi.org/10.62940/als.v13i1.4001
2026	Komy MHE, Aldosari BN, Zaki RM, Bafail R, Yusif RM, Abdelgawad MA, Elmowafy M, **Abuhelwa AY**, Eid HM. Intranasal co-delivery of riluzole and berberine via chitosan-coated PLGA nanoparticles for synergistic neuroprotection in Alzheimer's disease: formulation, characterization, and pharmacokinetics analysis. Naunyn Schmiedebergs Arch Pharmacol. 2026.https://doi.org/10.1007/s00210-026-05182-3
2026	Watad ZA, Zenati RA, Semreen AM, Alqudah MAY, **Abuhelwa AY**, Al Rawi AM, Al Hroub HM, Gharbiah EA, Aleidi SM, AlShareef ZM, Bustanji Y, El Huneidi W, Alzoubi KH, Semreen MH. Repurposing Amlodipine for Glioblastoma: A Proteomics study with relevance to pharmacy practice. Pharmacy Practice. 2026;24(1):1-18. https://doi.org/10.18549/PharmPract.2026.1.3357

September 2026 **Ahmad Abuhelwa**

YY	Selected publications
2026	Almehdi AM, Al-Daffaie FM, Sharaf BM, Guella A, Soares NC, Al-Hroub HM, El-Huneidi W, Y. Alqudah MA, **Abuhelwa AY**, Alzoubi KH, ... Integrating metabolomics into obesity care: towards biomarker guided pharmacy practice. Pharmacy Practice. 2026;24(1). https://pharmacypractice.org/index.php/pp/article/view/3428
2026	Al-Daffaie FM, Zenati RA, Alniss HY, Al-Hroub HM, El-Awady R, **Abuhelwa AY**, Ramadan WS, El-Huneidi W, Abu-Gharbieh E, Alzoubi KH, Bustanji Y, Semreen MH. Exploring the Impact of Two DNA Minor Groove Binder Compounds on HCT-116 Cells: A Comprehensive Multiomics Analysis Using Mass Spectrometry. Journal of Proteome Research. 2026;25(4):1999-2013. https://doi.org/10.1021/acs.jproteome.5c01039
2026	Aleidi SM, Y AH, Sharaf BM, Almasri FA, Al-Iede M, Al Zayadneh E, **Abuhelwa AY**, El-Huneidi W, Al Shareef Z, Abu-Gharbieh E, Alzoubi KH, Bustanji Y, Semreen MH. Untargeted metabolomics profiling of childhood asthma: linking metabolic pattern to disease severity. Mol Cell Pediatr. 2026;13(1):6. https://doi.org/10.1186/s40348-026-00219-2
2026	**Abuhelwa AY**, Almansour SA, Al-Shamsi HO, Abuhelwa Z, Alqudah MAY, Bustanji Y, Semreen MH, Alzoubi KH, Modi ND, McKinnon RA, Sorich MJ, Hopkins AM. Cardiovascular medications and treatment outcomes in multiple myeloma: insights from phase III clinical trials. Sci Rep. 2026;16(1): 7683. https://doi.org/10.1038/s41598-026-37464-4
2026	Kharaba Z, Alzoubi KH, Al-Azzam S, Al-Azayzih A, **Abuhelwa AY**, Jirjees F, Jarab A, Ramadan A, Altawalbeh SM, Rahhal D, Ahmed M, Ibrahim LA, Aldeyab MA, Alfoteih Y, Abuhammad S. Exploring patient satisfaction with community pharmacy services in the United Arab Emirates: Implications for quality improvement. PLoS One. 2026;21(1):e0339417. https://doi.org/10.1371/journal.pone.0339417
2026	Alkhoujah SM, Zenati RA, Ahmed M, **Abuhelwa AY**, Aleidi SM, Alqudah MAY, El-Huneidi W, Abu-Gharbieh E, AlShareef ZM, Alzoubi KH, Bustanji Y, Semreen MH. Integrative metabolomics and proteomics of heat stress. Clin Chim Acta. 2026;584:120869. https://doi.org/10.1016/j.cca.2026.120869
2026	Li LX, Shahnam A, Kichenadasse G, Murray L, Woodman R, **Abuhelwa AY**, Modi ND, Rowland A, Hopkins AM, Sorich MJ. Heterogeneous treatment effect of immune checkpoint inhibitors by pretreatment prognosis in randomized controlled trials. JNCI Cancer Spectr. 2026;10(2): pkaf127. https://doi.org/10.1093/jncics/pkaf127
2026	Tokatly RT, Sharaf BM, **Abuhelwa AY**, Soliman S, El Huneidi W, Alqudah MAY, Alzoubi KH, Abu Gharbieh E, Albsoul A, Bulatova N, Kasabri V, AlQuoqa R, Khawaja N, Hyassat D, Abujbara M, Basha A, El Khateeb M, Bustanji Y, Semreen MH. Enhancing Clinical Decision-Making in Gestational Diabetes Through Metabolomics: A Pharmacy Practice Outlook. Pharmacy Practice. 2026;24(1):1-14. https://doi.org/10.18549/PharmPract.2026.1.3344
2025	Li, L. X., A. M. Hopkins, R. Woodman, **A. Y. Abuhelwa**, Y. Gao, N. Parent, A. Rowland, and M. J. Sorich. Discrimination, Calibration, and Variable Importance in Statistical and Machine Learning Models for Predicting Overall Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. J Clin Epidemiol 2025. 190: p. 112082. https://dx.doi.org/10.1016/j.jclinepi.2025.112082
2025	Younes, H. M., A. A. Sallam, L. A. Saifan, A. M. Ghanem, E. A. Khalil, E. A. Abu-Basha, and **A. Y. Abuhelwa**. Development and Pharmacokinetic Evaluation of Newly Formulated Letrozole Non-Aqueous Nanoemulgel Transdermal Systems for Hormone-Dependent Breast Cancer Therapy. Pharmaceutics. 2025;17(11). https://dx.doi.org/10.3390/pharmaceutics17111444.
2025	Modi ND, **Abuhelwa AY**, Kuderer NM, Li LX, Lyman GH et al. Associations of Commonly Used Concomitant Medications With Survival and Adverse Event Outcomes in Breast Cancer. Cancer Medicine, 14 (21). https://doi.org/10.1002/cam4.71320

September 2026 **Ahmad Abuhelwa**

YY	Selected publications
2025	Kharaba, Zelal, Sayer Al-Azzam, Shoroq M Altawalbeh, Alin Alkwarit, Noor Abdulkareem Salmeh, Yassen Alfoteih, Mohammad Araydah, Hala Al-Obaidi, Feras Jirjees, and **Ahmad Abuhelwa** et al. Knowledge, attitude, and perception of antibiotic resistance among the United Arab Emirates residents after COVID-19 pandemic: A nationwide cross-sectional study. Pharmacy Practice, 2025. 23(3): p. 1-12. https://pharmacypractice.org/index.php/pp/article/view/3289
2025	Zenati RA, Soares NC, Alniss HY, Al-Hroub HM, El-Awady R, **Abuhelwa AY**, et al. Untargeted Multiomics of LNCaP Cell Line Treated with a Novel DNA Minor Groove Binder and/or Doxorubicin Using Mass Spectrometry. J Proteome Res, 24(10), 4911-4924. https://doi.org/10.1021/acs.jproteome.5c00135
2025	Rafii S., Mukherji D., Komaranchath AS, Khalil C, Iqbal F, Abdelwahab SI, Abyad A, **Abuhelwa AY**, Gandikota L, & Al-Shamsi HO. Advancing CAR T-Cell Therapy in Solid Tumors: Current Landscape and Future Directions. Cancers (Basel), 2025, 17(17). https://doi.org/10.3390/cancers17172898
2025	Menz BD., Modi ND, **Abuhelwa AY**, et al. Patient-reported outcome thresholds and their associations with survival, adverse events, and quality of life in a pooled analysis of breast cancer trials. Int J Cancer, 2025, 157(10), 2135-2145. https://doi.org/10.1002/ijc.70020
2025	Al-Daffaie FM, Al-Daffaie MM, **Abuhelwa AY**, et al., Exosomal biomarkers in cancer: Insights from Multi-OMIC approaches. Clin Chim Acta, 2025. 579: p. 120606. https://doi.org/10.1016/j.cca.2025.120606
2025	Hagyousif YA, Zenati RA, Soares NC, Al-Hroub HM, Khan FM, Qaisar R, Hamoudi R, El-Awady R, **Abuhelwa AY**, et al. Molecular Signatures of Xenograft Colorectal Cancer in Mice Treated with Topotecan: A Mass Spectrometry-Based Study. Toxicology Reports, V 14, June 2025. https://doi.org/10.1016/j.toxrep.2025.102045
2025	Alqudah MA, Yaseen MM, Alzoubi KH, Al-Husein BA, Bardaweel SK, **Abuhelwa AY**, et al. Metabolomic Analysis, Antiproliferative, Anti-Migratory, and Anti-Invasive Potential of Amlodipine in Lung Cancer Cells. Drug Design, Development and Therapy. 2025:1215–29. https://doi.org/10.2147/dddt.S484561
2025	**Abuhelwa AY**, Almansour SA, Brown JR, Al-Shamsi HO, Abuhelwa Z, Kharaba Z, et al. Statin use and survival in CLL/SLL treated with ibrutinib: pooled analysis of 4 randomized controlled trials. Blood Adv, 9(14), 3566-3575. https://doi.org/10.1182/bloodadvances.2024015287
2025	Modi ND, Li LX, Logan JM, Wiese MD, **Abuhelwa AY**, McKinnon RA, et al. The state of individual participant data sharing for the highest-revenue medicines. Clinical Trials. 2025;22(2):170–7. https://doi.org/10.1177/17407745241286147
2025	**Abuhelwa AY**, Almansour SA, Basch E, Al-Shamsi HO, Abuhelwa Z, Bustanji Y, et al. Predictive and Prognostic Significance of Patient-Reported Outcomes for Survival and Adverse Events in Daratumumab-Treated Multiple Myeloma. Eur J Haematol. 2025;114(6):1020–1031. https://doi.org/10.1111/ejh.14410

September 2026 **Ahmad Abuhelwa**

YY	Selected publications
2025	Menz BD, Modi ND, **Abuhelwa AY**, Ruanglertboon W, Vitry A, Gao Y, et al. Generative AI Chatbots for Reliable Cancer Information: Evaluating web-search, multilingual, and reference capabilities of emerging large language models. Eur J Cancer. 2025;218:115274. https://doi.org/10.1016/j.ejca.2025.115274
2025	Hassanein MM, Hagyousif YA, Zenati RA, Al-Hroub HM, Khan FM, **Abuhelwa AY**, et al. Metabolomics insights into doxorubicin and 5-fluorouracil combination therapy in triple-negative breast cancer: a xenograft mouse model study. Frontiers in Molecular Biosciences. 2025; 11:1517289. https://doi.org/10.3389/fmolb.2024.1517289
2025	Sorich MJ, Manning-Bennett AT, Li LX, Shahnam A, Kichenadasse G, Karapetis CS, **Abuhelwa AY**, et al. Tumour Mutational Burden and Immune Checkpoint Inhibitor Response in Non-small Cell Lung Cancer: A Continuous Modelling Approach. Target Oncol. 2025;20(2):361–369. https://doi.org/10.1007/s11523-024-01124-2
2025	Bou Malhab LJ, Harb AA, Eldohaji L, Taneera J, Al-Hroub HM, **Abuhelwa AY**, et al. Exploring the Anticancer Effect of Artemisia herba-alba on Colorectal Cancer: Insights From Eight Colorectal Cancer Cell Lines. Food Science & Nutrition. 2025;13(1):e4715. https://doi.org/10.1002/fsn3.4715
2024	Semreen AM, Alsoud LO, Semreen MH, Ahmed M, Al-Hroub HM, El-Awady R, Wafaa S Ramadan WS, **Abuhelwa AY**, et al. Multi-omics analysis revealed significant metabolic changes in brain cancer cells treated with paclitaxel and/or topotecan. Heliyon. 2024;10(21). https://doi.org/10.1016/j.heliyon.2024.e39420
2024	Abufares HI, Zenati RA, Soares NC, El-Huneidi W, Dahabiyeh LA, Al-Hroub HM, Alqudah MA, **Abuhelwa AY**, et al. A non-targeted metabolomics comparative study on plasma of pfizer and sinopharm COVID-19 vaccinated individuals, assessed by (TIMS-QTOF) mass spectrometry. Heliyon. 2024;10(15). https://doi.org/10.1016/j.heliyon.2024.e35443
2024	Almansour SA, Alqudah MA, Abuhelwa Z, Al-Shamsi HO, Alhuraiji A, Semreen MH, **Abuhelwa AY**, et al. Antithrombotic utilization, adverse events, and associations with treatment outcomes in multiple myeloma: pooled analysis of three clinical trials. Therapeutic Advances in Medical Oncology. 2024;16:17588359241275387. https://doi.org/10.1177/17588359241275387
2024	Mahmoud A, **Abuhelwa AY**, Owen T, Alazzawi A, Shara M, Alqudah MA, et al. Role of pharmacists in the care of adult asthma patients: A scoping review. Res Social Adm Pharm. 2024;20(9):860–869. https://doi.org/10.1016/j.sapharm.2024.06.005
2024	Al-Daffaie F., et al. **Abuhelwa AY**. Metabolomics and Proteomics in Prostate Cancer Research: Overview, Analytical Techniques, Data Analysis, and Recent Clinical Applications, International Journal of Molecular Sciences, 2024 https://doi.org/10.3390/ijms25105071
2024	Almansour S., et al. **Abuhelwa AY**. Association of proton pump inhibitor use with survival and adverse effects outcomes in patients with multiple myeloma: pooled analysis of three clinical trials, Scientific Reports 2024 V14(1) https://doi.org/10.1038/s41598-023-48640-1
2024	Bustanji Y, et al. **Abuhelwa AY**. Exploring the Global Landscape of Self-Medication Among Students: Trends, Risks, and Recommendations for Safe and Responsible Practices, Pharmacy Practice 2024 V22(1) https://doi.org/10.18549/PharmPract.2024.1.2928

September 2026 **Ahmad Abuhelwa**

YY	Selected publications
2023	Ashley M Hopkins; Natansh D Modi, **Abuhelwa AY**, Ganessan Kichenadasse, Nicole M Kuderer, Gary H Lyman, Michael D Wiese, Ross A McKinnon, Frank W Rockhold, Aaron Mann, Andrew Rowland, Michael J Sorich. Heterogeneity and Utility of Pharmaceutical Company Sharing of Individual-Participant Data Packages. JAMA Oncology 2023 October 5. doi:10.1001/jamaoncol.2023.3996
2023	Bustanji Y, et al. **Abuhelwa AY**, AlKhatib HS. Gold Nanoparticles and Breast Cancer: A bibliometric Analysis of the Current State of Re- search and Future Directions, OpenNano 2023 July V 12. https://doi.org/10.1016/j.onano.2023.100164
2023	Bustanji Y, et al. **Abuhelwa AY**, Abu-Zurayk R, AlKhatib HS. Analysis and mapping of global scientific research on human monkeypox over the past 20 years, Veterinary World 2023 V 16(4). doi: 10.14202/vetworld.2023.693-703
2023	Yousra A. Hagyousif, et al. **Abuhelwa AY**, Karem H. Alzoubi, Nelson C. Soares, and Mohammad H. Semreen. Skin Cancer Metabolic Profile Assessed by Different Analytical Platforms, International Journal of Molecular Sciences 2023 Jan 13;24(2):1604. https://doi.org/10.3390/ijms24021604
2023	Munazza Ahmed, et al. **Abuhelwa AY**, Mohammad H. Semreen, and Karem H. Alzoubi. Preclinical and Clinical Applications of Metabolomics and Proteomics in Glioblastoma Research, International Journal of Molecular Sciences 2023 Dec 25;24(1):348. https://doi.org/10.3390/ijms24010348
2023	Ruba A. Zenati, et al. **Abuhelwa AY**, Nelson C. Soares, and Mohammad H. Semreen. Evaluation of Two Simultaneous Metabolomic and Proteomic Extraction Protocols Assessed by Ultra-High- Performance Liquid Chromatography Tandem Mass Spectrometry, International Journal of Molec- ular Sciences 2023 Jan 10;24(2):1354. https://doi.org/10.3390/ijms24021354
2023	Daraghmeh D, Hopkins AM, King C, **Abuhelwa AY**, Wechalekar M, Proudman S, Sorich MJ, Wiese MD. Female reproductive status and exogenous sex hormone use in rheumatoid arthritis patients treated with tocilizumab and csDMARDs, Rheumatology 2023 V 62(2). https://doi.org/10.1093/rheumatology/keac357
2022	Ziad Abuhelwa, Anas Alsughayer **Abuhelwa AY**, et al. In-Hospital Mortality and Morbidity in Cancer Patients with COVID-19: A Nationwide Analysis from the United States, Cancers 2022 Dec 30;15(1):222. https://doi.org/10.3390/cancers15010222
2022	Ahlam M. Semreen, et al. **Abuhelwa AY**, Mohammad H. Semreen, and Karem H. Al-zoubi. Metabolomics Analysis Revealed Significant Metabolic Changes in Brain Cancer Cells Treated with Paclitaxel and/or Etoposide, International Journal of Molecular Sciences. https://doi.org/10.3390/ijms232213940
2022	Kamel B, **Abuhelwa AY**,Foster DJR, Dong JK, Graham GG, Williams KM, Pile KD, Day RO. Population pharmacokinetic modelling of febuxostat in healthy subjects and people with gout, British Journal of Clinical Pharmacology 2022 V 88(12) https://doi.org/10.1111/bcp.15462
2022	Modi ND, **Abuhelwa AY**, McKinnon RA, Boddy AV, Wiese MD, Hoffmann TC, Perakslis ED, Rowland A, Sorich MJ, Hopkins AM. Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration, JAMA Oncology doi:10.1001/jamaoncol.2022.2867

September 2026 **Ahmad Abuhelwa**

YY	Selected publications
2022	Manning-Bennett AT, Hopkins AM, Sorich MJ, Proudman SM, Foster DJR, **Abuhelwa AY**, Wiese MD. The association between depression and anxiety with treatment outcomes in patients with rheumatoid arthritis - a pooled analysis of five randomised controlled trials, Therapeutic Advances in Musculoskeletal Disease 2022 Jul 22;14:1759720X221111613.
2022	**Abuhelwa AY**, Bellmunt J., et al. C-reactive protein provides superior prognostic accuracy than the IMDC risk model in renal cell carcinoma treated with Atezolizumab/Bevacizumab, Frontiers in Oncology. 2022. https://doi.org/10.3389/fonc.2022.918993
2022	**Abuhelwa AY**, Somogyi A., Loo CK, et al. Population pharmacokinetics and pharmacodynamics ofthe therapeutic and adverse effects of ketamine in patients with treatment-refractory depression,CPT: Clinical Pharmacology and Therapeutics https://doi.org/10.1002/cpt.2640
2022	Modi ND, Dannel NO, Perry RN, **Abuhelwa AY**, [..], Swain SM, Welslau M, Sorich MJ, Hopkins AM. Patient-reported outcomes predict survival and adverse events following anticancer medicines initiation in advanced HER2-positive breast cancer, ESMO Open. 2022;7(3):100475. https://doi.org/10.1016/j.esmoop.2022.100475
2022	**Abuhelwa AY**, et al. A clinical scoring tool validated with machine learning for predicting severe hand-foot syndrome from sorafenib in hepatocellular carcinoma, Cancer Chemotherapy and Phar- macology doi: 10.1007/s00280-022-04411-9
2022	Sarah Badaoui, Adel Shahnam, **Abuhelwa AY**, et al. The predictive utility of patient-reported outcomes and performance status for survival in metastatic lung cancer patients treated with chemoimmunotherapy, Translational Lung Cancer Research 11(3):432-439. Doi: 10.21037/tlcr-21-938.
2022	**Abuhelwa AY**, Bellmunt J., Kichenadasse G, McKinnon RA, Rowland A, Sorich MJ, Hopkins AM. Enhanced Bellmunt risk score for survival prediction in urothelial carcinoma treated with im- munotherapy, Clinical Genitourinary Cancer. https://doi.org/10.1016/j.clgc.2021.11.010
2022	Hopkins AM, **Abuhelwa AY**, McKinnon RA, Kichenadasse G, Logan JM, Rowland A, Sorich MJ. Smoking and immunotherapy efficacy in lung cancer by PDL1 subgroups: An individual participant data meta-analysis of atezolizumab clinical trials: Smoking and immunotherapy efficacy in lung cancer, European Journal of Cancer. doi: 10.1016/j.ejca.2021.10.020
2022	Hopkins AM, Kichenadasse G, McKinnon RA, **Abuhelwa AY**, Logan JM, Badaoui S, Karapetis CS, Rowland A, Sorich MJ. Efficacy of first-line atezolizumab combination therapy in patients with non- small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150, British Journal of Cancer. doi: 10.1038/s41416-021-01606-4
2021	Tan E, **Abuhelwa AY** [equal first author], et al. Association between patient-reported outcomes and survival in patients with advanced urothelial carcinoma treated with atezolizumab, Bladder Cancer, DOI 10.3233/BLC-211613.
2021	Natansh Modi, **Abuhelwa AY**, et al. Commentary: Association Between Antihypertensive Medi- cation Use and Breast Cancer: A Systematic Review and Meta-Analysis, Front Pharmacol. 2021;12:732622. https://doi.org/10.3389/fphar.2021.609901

September 2026 **Ahmad Abuhelwa**

YY	Selected publications
2021	Asha Kapetas, **Abuhelwa AY** [equal first author], McKinnon RA, Rowland A, Sorich MJ, Hopkins AM. Evidence based guidelines for drug interaction studies: Model informed time course of in- testinal and hepatic CYP3A4 inhibition by clarithromycin, AAPS Journal DOI : 10.1208/s12248-021-00632-7
2021	Hopkins AM, Kichenadasse G, **Abuhelwa AY**, McKinnon RA, Rowland A, Sorich MJ. Reply to Com-ment on Hopkins AL et al. Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IM- POWER150 Trial". Cancers, 2021, 13(5), 1176, Cancers. 13(15):3763 https://doi.org/10.3390/cancers13153763
2021	Louise Ladebo, **Abuhelwa AY**, Foster DJR, Kroustrup JP, Pacyk GJ, Kongstad KT, Drewes,AM, Christrup LL, Olesen AE. Effect of Roux-en-Y gastric bypass on the pharmacokinetic- pharmacodynamic relationships of liquid and controlled-release formulations of oxycodone, Basic and Clinical Pharmacology and Toxicology, doi: 10.1111/bcpt.13634
2021	**Abuhelwa AY**, Kichenadasse G, McKinnon RA, Rowland A, Hopkins AM, Sorich MJ. Machine learning for prediction of survival outcomes with immune check point inhibitors in urothelial cancer, Cancers, 13(9): 2021 https://doi.org/10.3390/cancers13092001
2021	Modi ND, **Abuhelwa AY** [equal first-author], Badaoui S, Shaw E, Shankaran K, McKinnon RA, Rowland A, Sorich MJ, Hopkins. Prediction of severe neutropenia and diarrhoea in breast cancer pa- tients treated with abemaciclib, The Breast,58:57-62 https://doi.org/10.1016/j.breast.2021.04.003
2021	**Abuhelwa AY**, Foster DJR, Manning-Bennett A, Sorich MJ, Proudman S, Wiese MD, Hopkins AM. Concomitant beta-blocker use is associated with a reduced rate of remission in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs: a post-hoc multicohort analysis, Therapeutic advances in Musculoskeletal diseases, Volume 13: 1759720X211009020 https://doi.org/10.1177/1759720X211009020
2021	Hopkins AM, Kichenadasse G, **Abuhelwa AY**, McKinnon RA, Rowland A, Sorich MJ. Value of the Lung Immune Prognostic Index in patients with non-small cell lung cancer initiating first-line atezolizumab combination therapy: subgroup analysis of the IMpower150 trial, Cancers, 13 (5) 10.3390/cancers13051176 https://doi.org/10.3390/cancers13051176
2021	Natansh Modi,Tan JQE, Rowland A, Koczwara B., **Abuhelwa AY**, Kichenadasse G, McKinnon RA, Wiese MD, Sorich MJ, Hopkins AM. The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data, npj Breast Cancer, 7(1):30. doi: 10.1038/s41523-021-00241-9
2021	**Abuhelwa AY**, Hopkins AM, Sorich MJ, Proudman S, Foster DJR, Wiese MD. Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti- rheumatic drugs, Scientific Reports,10(1): 18634 https://doi.org/10.1038/s41598-020-75673-7
2021	Upton RN, Hopkins AM, **Abuhelwa AY**, Hughes JH, Foster DJR. Physiologically based models: techniques and applications to drug delivery. In: Berner B, Gordi T, Benson HAE, Roberts MS, editors. Drug Delivery Approaches: Perspectives from Pharmacokinetics and Pharmacodynamics. John Wiley & Sons; 2021. p. 43–73. https://doi.org/10.1002/9781119772767.ch2
2020	Fouladian P , Kohlhagen J , Arafat M , Afinjuomo F , Workman N , **Abuhelwa AY**, Song Y , GargS , Blencowe A . Three-dimensional Printed 5-Fluorouracil Eluting Polyurethane Stents for the Treatment of Oesophageal Cancers, Biomaterials Science, 8(23): 6625-6636 https://doi.org/10.1039/D0BM01355B

September 2026 **Ahmad Abuhelwa**

YY	Selected publications
2020	Meola TR, **Abuhelwa AY**, Joyce P, Clifton P, Prestidge CA. A safety, tolerability, and pharmacokinetic study of a novel simvastatin silica-lipid hybrid formulation in healthy male participants, Drug Delivery and Translational Research,11(3):1261-1272 https://doi.org/10.1007/s13346-020-00853-x
2020	Wiese MD, Manning-Bennett AT, **Abuhelwa AY**. IRAK-4 Inhibitors in the Treatment of Rheumatoid Arthritis, Expert Opinion on Investigational Drugs, 29(5):475-482 https://doi.org/10.1080/13543784.2020.1752660
2020	Ladebo L, Foster DJR, **Abuhelwa AY**, Upton RN, Kongstad KT, Drewes AM, Christrup LL, Olesen AE. Population pharmacokinetic-pharmacodynamic modelling of immediate and controlled-release formulations of oxycodone in healthy subjects, Basic and Clinical Pharmacology and Toxicology, 126(3):263-276. https://doi.org/10.1111/bcpt.13330
2019	**Abuhelwa AY**, Mudge S, Upton RN, Foster DJR. Mechanistic assessment of the effect of omeprazole on the in vivo pharmacokinetics of itraconazole in healthy volunteers, European Journal of Drug Metabolism and Pharmacokinetics, 2018. p. 1-15. https://doi.org/10.1007/s13318-018-0519-1
2018	**Abuhelwa AY**, Mudge S, Upton RN, Foster DJR. Population in vitro-in vivo pharmacokinetic model of first-pass metabolism: itraconazole and hydroxy-itraconazole, Journal of Pharmacokinetics and Pharmacodynamics, 2018. 45 (2):181-197. https://doi.org/10.1007/s10928-017-9555-8
2017	Hopkins AM, Wojciechowski J, **Abuhelwa AY**, Mudge S, Upton RN, Foster DJ. Population Pharmacokinetic Model of Doxycycline Plasma Concentrations - Pooled Study Data, Antimicrobial Agents and Chemotherapy, 2017. AAC. 02401-16. https://doi.org/10.1128/aac.02401-16
2017	**Abuhelwa AY**, Williams DB, Upton RN, Foster DJ. Food, gastrointestinal pH, and models of oral drug absorption, European Journal of Pharmaceutics and Biopharmaceutics, 2017. 112: 234-48. https://doi.org/10.1016/j.ejpb.2016.11.034
2016	Upton RN, Foster DJ, **Abuhelwa, AY**. An introduction to physiologically based pharmacokinetic models, Pediatric Anesthesia, 2016. 26: 1036-46 https://doi.org/10.1111/pan.12995
2016	**Abuhelwa AY**, Foster DJR, Upton RN. A Quantitative review and meta-models of the variability and factors affecting oral drug absorption-part I: Gastrointestinal pH, The AAPS Journal, 2016. 18(5),1309-1321 https://doi.org/10.1208/s12248-016-9952-8
2016	**Abuhelwa AY**, Foster DJR, Upton RN. A Quantitative review and meta-models of the variability and factors affecting oral drug absorption-part II: Gastrointestinal transit time, The AAPS Journal, 2016. 18(5), 1322-1333. https://doi.org/10.1208/s12248-016-9953-7
2016	**Abuhelwa AY**, Mudge S, Hayes D, Upton RN, Foster DJ. Population in vitro-in vivo correlation model linking gastrointestinal transit time, pH, and pharmacokinetics: itraconazole as a model drug, Pharmaceutical Research, 2016. 33(7), 1782-1794. https://doi.org/10.1007/s11095-016-1917-1

September 2026 **Ahmad Abuhelwa**

YY	Selected publications
2015	**Abuhelwa AY**, Foster DJ, Mudge S, Hayes D, Upton RN. Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and Sporanox capsule formula- tions in healthy subjects in fed and fasted states, Antimicrobial Agents and Chemotherapy, 2015. 59(9), 5681-5696 https://doi.org/10.1128/aac.00973-15
2015	**Abuhelwa AY**, Foster DJ, Upton RN. ADVAN-style analytical solutions for common pharmacokinetic models., Journal of Pharmacological and Toxicological Methods, 2015. 73, 42-48 https://doi.org/10.1016/j.vascn.2015.03.004
2011	Bani-Jaber AK, Alkawareek, MY, Al-Gousous JJ, **Abu Helwa, AY**. Floating and sustained-Release characteristics of effervescent tablets prepared with a mixed matrix of eudragit L-100-55 and eudragit E PO, Chemical and Pharmaceutical Bulletin, 2011. 59(2), 155-160 https://doi.org/10.1248/cpb.59.155

PROFESSIONAL MEMBERSHIPS

YY	Name of Organization / Society
2021 – Present	Full Member, FIP – The International Pharmaceutical Federation
2021 – Present	Biostatistical Editor, Therapeutic Advances in Musculoskeletal Disease
2021 – 2022	Executive Member, Early-Mid Career Academicians (EMCA) Committee, Flinders University
2020 – Present	Full Member, Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT)
2020 – Present	Full Member, Australasian Pharmaceutical Science Society (APSA)
2019	Organizing Committee Member, Adelaide Pharmacology Group (APG)
2019 – 2023	Executive Member, PAGANZ Inc. Committee
2018 – 2020	Member, Research Executive Committee, School of Pharmacy, University of South Australia
2014 – Present	General Member, Population Approach Group of Australia and New Zealand (PAGANZ)